<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">pmj</journal-id><journal-title-group><journal-title xml:lang="ru">Тихоокеанский медицинский журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Pacific Medical Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1609-1175</issn><publisher><publisher-name>TGMU</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.34215/1609-1175-2023-1-59-63</article-id><article-id custom-type="elpub" pub-id-type="custom">pmj-2473</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL RESEARCHES</subject></subj-group></article-categories><title-group><article-title>Антибактериальное и антибиопленочное действия бактериофагов в отношении Klebsiella pneumoniae и Pseudomonas aeruginosa, выделенных от пациентов с ортопедической инфекцией</article-title><trans-title-group xml:lang="en"><trans-title>Anti-bacterial and anti-biofilm activity of bacteriophages against Klebsiella pneumoniae and Pseudomonas aeruginosa isolated from orthopedic patients</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2326-7413</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гордина</surname><given-names>Е. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Gordina</surname><given-names>E. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гордина Екатерина Михайловна – канд. мед. наук, старший научный сотрудник отделения профилактики и лечения раневой инфекции </p><p>195427, г. Санкт-Петербург, ул. Академика Байкова, 8</p></bio><bio xml:lang="en"><p>Ekaterina M. Gordina, Cand. Sci. (Med.), Senior Researcher of the Division of Wound Infection Treatment and Prevention</p><p>8, Akademika Baykova str., St. Petersburg, 195427</p></bio><email xlink:type="simple">emgordina@win.rniito.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Божкова</surname><given-names>С. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Bozhkova</surname><given-names>S. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>St. Petersburg</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Смирнова</surname><given-names>Л. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Smirnova</surname><given-names>L. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>St. Petersburg</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Национальный медицинский исследовательский центр травматологии и ортопедии им. Р.Р. Вредена</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Vreden National Medical Research Center of Traumatology and Orthopedics</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>14</day><month>04</month><year>2023</year></pub-date><volume>0</volume><issue>1</issue><fpage>59</fpage><lpage>63</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Гордина Е.М., Божкова С.А., Смирнова Л.Н., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Гордина Е.М., Божкова С.А., Смирнова Л.Н.</copyright-holder><copyright-holder xml:lang="en">Gordina E.M., Bozhkova S.A., Smirnova L.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.tmj-vgmu.ru/jour/article/view/2473">https://www.tmj-vgmu.ru/jour/article/view/2473</self-uri><abstract><sec><title>Цель</title><p>Цель: оценить чувствительность К. pneumoniae и P. aeruginosa к препарату поливалентного бактериофага и его влияние на биопленкообразование и сформированную биопленку штаммов, выделенных от пациентов с ортопедической инфекцией.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Протестировано 50 клинических изолятов K. pneumoniae и 50 – P. aeruginosa. Идентификацию выполняли методом MALDI-TOF-MS, антибиотикочувствительность оценивали в соответствии с EUCAST v.21. Детекцию генов карбапенемаз осуществляли методом ПЦР в реальном времени. Чувствительность клинических штаммов к поливалентному пиобактериофагу определяли методом спот-теста, а K. pneumoniae ATCC 33495 и P. aeruginosa – ATCC 27853 при оценке кинетических кривых роста. Биопленки чувствительных к бактериофагам штаммов формировали по методу O’Toole путем совместной инкубации бактерий с фагами. Влияние бактериофагов на 24-часовые биопленки оценивали сравнением оптической плотности экстрактов красителя обработанных бактериофагом лунок и контрольных при 570 нм.</p></sec><sec><title>Результаты</title><p>Результаты. 7 (14%) клинических штаммов K. pneumoniae и 15 (30%) P. aeruginosa были устойчивы к карбапенемам. 6 изолятов K. pneumoniae продуцировали NDM-кабапенемазы, 4 изолята P. aeruginosa – VIM-карбапенемазы. Коммерческий препарат бактериофага был активен в отношении 36% и 56% штаммов K. pneumoniae и P. aeruginosa соответственно, включая 1 из 6 и 4 из 15 карбапенем-устойчивых изолятов. Большинство изученных штаммов снижали продукцию биопленок при совместной инкубации с фагом, однако снижение биомассы более 80% выявлено только для P. aeruginosa. Воздействие бактериофага на уже сформированные биопленки было менее выраженным, несмотря на снижение биомассы биопленок у 78% и 68% штаммов K. pneumoniae и P. aeruginosa соответственно.</p></sec><sec><title>Заключение</title><p>Заключение. Полученные результаты свидетельствуют о перспективности дальнейших исследований, посвященных изучению активности бактериофагов в отношении возбудителей ортопедической имплантат-ассоциированной инфекции, и разработки методов фаготерапии для лечения профильных пациентов.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Objective</title><p>Objective. To investigate the susceptibility of K. pneumoniae and P. aeruginosa to a polyvalent bacteriophage preparation and its effect on biofilm formation and the strain biofilms isolated from orthopedic patients.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. The research sample included 50 clinical isolates of K. pneumoniae and 50 clinical isolates of P. aeruginosa. Identification was performed by MALDI-TOF-MS; antibiotic susceptibility was assessed in accordance with EUCAST v 21. Detection of carbapenemase genes was carried out by real-time PCR. The strain susceptibility to the bacteriophage was determined by a spot test; K. pneumoniae ATCC 33495 and P. aeruginosa ATCC 27853 were determined by assessing their growth curves. Biofilms of strains sensitive to bacteriophages were formed according to the O’Toole method by co-incubation of bacteria with phages. The effect of bacteriophages on 24-hour biofilms was assessed by comparing the optical density of dye extracts of bacteriophage-treated wells and control wells at 570 nm. The data were analyzed using the Statistica environment.</p></sec><sec><title>Results</title><p>Results. It was found that 7 (14%) of K. pneumoniae and 15 (30%) of P. aeruginosa were resistant to carbapenems. Six strains of K. pneumoniae produced NDM-cabapenemase, while four isolates of P. aeruginosa produced VIM-carbapenemases. The bacteriophage preparation under study was active against 36% and 56% of K. pneumoniae and P. aeruginosa strains, respectively. The majority of the studied strains reduced biofilm production upon co-incubation with a phage; however, a decrease in biomass of greater than 80% was observed only for P. aeruginosa. The effect of the bacteriophage on the already formed biofilms was less pronounced, despite a decrease in the biofilm biomass in 78% and 68% of K.pneumoniae and P. aeruginosa strains, respectively.</p></sec><sec><title>Conclusion</title><p>Conclusion. The results obtained confirm the need for further research into the action of bacteriophages against pathogens caused by implant-associated infections and the development of bacteriophage therapy for orthopedic patients.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>бактериофаг</kwd><kwd>Klebsiella pneumoniae</kwd><kwd>Pseudomonas aeruginosa</kwd><kwd>имплантат-ассоциированная инфекция</kwd><kwd>карбапенемазы</kwd></kwd-group><kwd-group xml:lang="en"><kwd>bacteriophage</kwd><kwd>Klebsiella pneumoniae</kwd><kwd>Pseudomonas aeruginosa</kwd><kwd>implant-associated infection</kwd><kwd>carbapenemases</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">авторы заявляют об отсутствии внешнего финансирования при проведении исследования.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Gordillo Altamirano FL, Barr JJ. Phage therapy in the postantibiotic era. Clin Microbiol Rev. 2019;32(2):e00066-18. doi: 10.1128/CMR.00066-18</mixed-citation><mixed-citation xml:lang="en">Gordillo Altamirano FL, Barr JJ. Phage therapy in the postantibiotic era. Clin Microbiol Rev. 2019;32(2):e00066-18. doi: 10.1128/CMR.00066-18</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Patey O, McCallin S, Mazure H, Liddle M, Smithyman A, Dublanchet A. Clinical indications and compassionate use of phage therapy: personal experience and literature review with a focus on osteoarticular infections. Viruses. 2018;11(1):18. doi: 10.3390/v11010018</mixed-citation><mixed-citation xml:lang="en">Patey O, McCallin S, Mazure H, Liddle M, Smithyman A, Dublanchet A. Clinical indications and compassionate use of phage therapy: personal experience and literature review with a focus on osteoarticular infections. Viruses. 2018;11(1):18. doi: 10.3390/v11010018</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629–55. doi: 10.1016/S01406736(21)02724-0</mixed-citation><mixed-citation xml:lang="en">Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629–55. doi: 10.1016/S01406736(21)02724-0</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Ландышев Н.Н., Воронько Я.Г., Тимошина О.Ю., Суслина С.Н., Акимкин В.Г., Мирошников К.А. Обзор законодательства в области обращения персонализированных препаратов бактериофагов. Вопросы вирусологии. 2020;65(5):259–66. doi: 10.36233/0507-4088-2020-65-5-2</mixed-citation><mixed-citation xml:lang="en">Landyshev NN, Voronko YG, Timoshina OY, Suslina SN, Akimkin VG, Miroshnikov KA. A review of the regulatory framework for personalized bacteriophages registration. Problems of Virology. 2020;65(5):259–66 (In Russ.). doi: 10.36233/0507-4088-2020-65-5-2</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Bozhkova S, Tikhilov R, Labutin D, Denisov A, Shubnyakov I, Razorenov V, Artyukh V, Rukina A. Failure of the first step of two-stage revision due to polymicrobial prosthetic joint infection of the hip. J Orthop Traumatol. 2016;17(4):369–76. doi: 10.1007/s10195-016-0417-8</mixed-citation><mixed-citation xml:lang="en">Bozhkova S, Tikhilov R, Labutin D, Denisov A, Shubnyakov I, Razorenov V, Artyukh V, Rukina A. Failure of the first step of two-stage revision due to polymicrobial prosthetic joint infection of the hip. J Orthop Traumatol. 2016;17(4):369–76. doi: 10.1007/s10195-016-0417-8</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Harper DR, Parracho HMRT, Walker J, Sharp R, Hughes G, Werthén M, Lehman S, Morales S. Bacteriophages and biofilms. Antibiotics (Basel). 2014;3(3):270–84. doi: 10.3390/antibiotics3030270</mixed-citation><mixed-citation xml:lang="en">Harper DR, Parracho HMRT, Walker J, Sharp R, Hughes G, Werthén M, Lehman S, Morales S. Bacteriophages and biofilms. Antibiotics (Basel). 2014;3(3):270–84. doi: 10.3390/antibiotics3030270</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Hemmati F, Rezaee MA, Ebrahimzadeh S, Yousefi L, Nouri R, Kafil HS, Gholizadeh P. Novel strategies to combat bacterial bio-films. Mol Biotechnol. 2021;63(7):569–86. doi: 10.1007/s12033-021-00325-8</mixed-citation><mixed-citation xml:lang="en">Hemmati F, Rezaee MA, Ebrahimzadeh S, Yousefi L, Nouri R, Kafil HS, Gholizadeh P. Novel strategies to combat bacterial bio-films. Mol Biotechnol. 2021;63(7):569–86. doi: 10.1007/s12033-021-00325-8</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Тапальский Д.В. Чувствительность госпитальных изолятов Pseudomonas aeruginosa к препаратам для фаготерапии. Вестник витебского государственного медицинского университета. 2018;17(2):47–54. doi: 10.22263/2312-4156.2018.2.47</mixed-citation><mixed-citation xml:lang="en">Tapalski DV. Sensitivity of Pseudomonas aeruginosa nosocomial isolates to the preparations for phagotherapy. Vitebsk Medical Journal. 2018;17(2):47–54 (In Russ.). doi: 10.22263/2312-4156.2018.2.47</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Тапальский Д.В., Козлова А.И. Чувствительность к препаратам бактерирофагов клинических изолятов Klebsiella pneumoniae с различными уровнями антиби отикорезистентности. Проблемы здоровья и экологии. 2018;(1):56–62. doi: 10.51523/2708-6011.2018-15-1-9</mixed-citation><mixed-citation xml:lang="en">Tapalsky DV, Kozlova AI. Sensitivity of Klebsiella pneumoniae clinical isolates with various levels of antibiotic resistance to bacteriophage preparations. Health and Ecology Issues. 2018;1(55):56–62 (In Russ.). doi: 10.51523/2708-6011.2018-15-1-9</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Łusiak-Szelachowska M, Weber-Dąbrowska B, Górski A. Bacteriophages and lysins in biofilm control. Virol Sin. 2020;35(2):125–33. doi: 10.1007/s12250-019-00192-3</mixed-citation><mixed-citation xml:lang="en">Łusiak-Szelachowska M, Weber-Dąbrowska B, Górski A. Bacteriophages and lysins in biofilm control. Virol Sin. 2020;35(2):125–33. doi: 10.1007/s12250-019-00192-3</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">González S, Fernández L, Gutiérrez D, Campelo AB, Rodríguez A, García P. Analysis of different parameters affecting diffusion, propagation and survival of staphylophages in bacterial biofilms. Front Microbiol. 2018;9:2348. doi: 10.3389/fmicb.2018.02348</mixed-citation><mixed-citation xml:lang="en">González S, Fernández L, Gutiérrez D, Campelo AB, Rodríguez A, García P. Analysis of different parameters affecting diffusion, propagation and survival of staphylophages in bacterial biofilms. Front Microbiol. 2018;9:2348. doi: 10.3389/fmicb.2018.02348</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Асланов Б.И., Зуева Л.П., Долгий А.А., Конев С.Д., Гришко Т.А. Эффективность применения бактериофагов против штаммов Pseudomonas aeruginosa, формирующих микробные биопленки. Профилактическая и клиническая медицина. 2020;4(77):40–5. doi: 10.47843/2074-9120_2020_4_40</mixed-citation><mixed-citation xml:lang="en">Aslanov BI, Zueva LP, Dolgiy AA. Efficacy of bacteriophages against Pseudomonas aeruginosa biofiolms. Preventive and Clinical Medicine. 2020;4(77):40–5 (In Russ.). doi: 10.47843/2074-9120_2020_4_40</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Глазунов Е.А., Зубаров Ф.М., Павлова И.В., Толмачева Г.С. Воздействие вирулентными бактериофагами на биопленки Klebsiella pneumoniae. Проблемы ветеринарной санитарии, гигиены и экологии. 2020;4(36):480–5. doi: 10.36871/vet.san.hyg.ecol.202004012</mixed-citation><mixed-citation xml:lang="en">Glazunov EA, Zurabov FM, Pavlova, IB, Tolmacheva GS. Effects of the virulent bacteriophages on Klebsiella pneumoniae biofilms. Problems of Veterinary Sanitation, Hygiene and Ecology. 2020;4(36):480–5 (In Russ.). doi: 10.36871/vet.san.hyg.ecol.202004012</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Fong SA, Drilling A, Morales S, Cornet ME, Woodworth BA, Fokkens WJ, Psaltis AJ, Vreugde S, Wormald PJ. Activity of bacteriophages in removing biofilms of Pseudomonas aeruginosa isolates from chronic rhinosinusitis patients. Front Cell Infect Microbiol. 2017;7:418. doi: 10.3389/fcimb.2017.00418.</mixed-citation><mixed-citation xml:lang="en">Fong SA, Drilling A, Morales S, Cornet ME, Woodworth BA, Fokkens WJ, Psaltis AJ, Vreugde S, Wormald PJ. Activity of bacteriophages in removing biofilms of Pseudomonas aeruginosa isolates from chronic rhinosinusitis patients. Front Cell Infect Microbiol. 2017;7:418. doi: 10.3389/fcimb.2017.00418.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
